Study on hepatitis B virus reactivation in primary liver cancer after transcatheter arterial chemoembolization
LI Jing
JIANG Liping
TANG Shiwei
LIU Bingyuan
Abstract：Objective To explore the influencing factors of hepatitis B virus (HBV) reactivation in primary liver cancer (PLC) patients after transcatheter arterial chemoembolization (TACE). Methods 55 cases of PLC during October 2014 to August 2015 were recruited. Took their gender, age, tumor size, liver function, tumor marker α-fetoprotein (AFP), preoperative HBV DNA load, portal vein tumor thrombus, dosage of lipiodol and operation method (whether or not used micro catheter for super selective intubation) in operation, etc. as research factors and statistically analyzed. Results Single factor analysis results showed that alanine aminotransferase (ALT), total bilirubin (TBIL), preoperative AFP, preoperative HBV DNA high load, and dosage of lipiodol were all statistically significant for HBV reactivation (P ≤ 0.05) ; Multiple factors analysis showed that dosage of lipiodol more than 10 ml was the greatest risk factor for HBV reactivation [odd ratio(OR)=30.048,95% confidence interval(CI) (3.438~262.625)]. Conclusions TACE may cause HBV reactivation in PLC patients, which may be related to dosage of lipiodol, HBV DNA high load and high AFP before operation, etc. Therefore, all aspects should be comprehensively considered before TACE operation, appropriately use of lipiodol, positively detect and control of HBV DNA load, to prevent liver function damage for HBV reactivation and affect patients’prognosis.
Keywords：primary liver cancertranscatheter arterial chemoembolizationhepatitis B virusreactivation
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 25-28 )